Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-18
SponsorIRCCS Burlo Garofolo
About this trial
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
Eligibility criteria
Qualifiers
Paediatric oncological patients 0-18 years
Planned start of anthracycline therapy
Normal left ventricular systolic function according to International Guidelines before the treatment with AC
Disqualifiers
Previous anthracycline treatment, bone marrow transplantation or chest radiation
More than mild pericardial effusion
More than mild mitral regurgitation
Poor echocardiographic acoustic window
Trial design
Treatments tested in this trial
- Not listed
Trial groups
22 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov